Results 291 to 300 of about 373,608 (350)

A Mussel‐Inspired Bioadhesive Patch to Selectively Kill Glioblastoma Cells

Advanced Science, EarlyView.
An innovative mussel‐inspired bioadhesive patch has been developed for post‐surgical glioblastoma treatment. The patch, which adheres strongly in biological environments, releases a localized treatment. This treatment, acting via reactive oxygen species, shows specific toxicity to glioblastoma cells.
Jose Bolaños‐Cardet, Sara Pugliese, Jordi Bruna, Daniel Ruiz‐Molina, Salvio Suárez‐García, Victor J. Yuste   +5 more
wiley   +1 more source

Sphingosine-1-phosphate receptor 2 inhibition ameliorates familial exudative vitreoretinopathy models. [PDF]

J Biol Chem
Feridooni HA, Fody R, Tavasoli M, Alkandari M, van der Ende S, Nader M, Robitaille JM, McMaster CR.   +7 more
europepmc   +1 more source

LncRNA PVT1 targets miR-143-3p to modulate endothelial cell function and thereby participate in deep vein thrombosis (DVT) of the lower limbs. [PDF]

Ann Hematol
Xiang J, Zhang Y, Liu S, Xu Y, Cui W, Tao Y.   +5 more
europepmc   +1 more source

Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications. [PDF]

Biochem Biophys Rep
Das J, Barman B, Sarma P, Das BK, Chetia R, Kalita PP.   +5 more
europepmc   +1 more source

Secretory leukocyte protease inhibitor (SLPI) promotes cholangiocarcinoma progression via inflammation-associated and vasculogenic mechanisms. [PDF]

PLoS One
Chueajedton K, Chueaiphuk C, Inpad J, Kumphune S, Kaewkong W, Surangkul D, Sawanyawisuth K, Cha'on U, Phimsen S.   +8 more
europepmc   +1 more source

Cancer-derived fucosylated exosomal miR-6842-3p as a novel marker promotes ESCC angiogenesis and metastasis via the PTEN/AKT/mTOR/IRF1/CXCL10 axis. [PDF]

Oncogene
Chen J, Chen J, Lv X, Chen X, Ming L, Huang X, Wen F, Tang H, Gao Q, Liu C, Weng J, Huang Z, Zheng Y, Lin F, Chen W, Shang X, Yu C, Huang Y.   +17 more
europepmc   +1 more source

Role of histone acetylation in the regulation of CD36 and ANGPTL1 in esophageal squamous cell carcinoma. [PDF]

BMC Cancer
Baba AM, Shyanti RK, Hajam MA, Nissa N, Muzaffar M, Bashir T, Fida S, Abdullah M, Singh RP, Dar NA.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Angiogenesis inhibitors

Current Oncology Reports, 2000
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block ...
T R, Tennant, C W, Rinker-Schaeffer, W M, Stadler   +2 more
openaire   +4 more sources

Inhibitors of Angiogenesis

Nature Biotechnology, 1991
Angiogenesis, the formation of new capillaries, is essential to a number of important physiological events, both normal and pathological. Recently, increased attention has focused on the purification and characterization of inhibitors of this process, because of the potential therapeutic value of angiogenesis inhibitors in controlling such "angiogenic ...
M A, Moses, R, Langer
openaire   +2 more sources

Inhibitors of angiogenesis

Clinical and Translational Oncology, 2006
Angiogenesis and neovascularization are important mechanisms for tumor growth, progression and, subsequent metastasis. Cancer cells, as part of an inflammatory process, produce and induce multiple molecules (proangiogenic and antiangiogenic) from the surrounding stromal cells. Vascular Endothelial Growth Factor (VEGF) is the most relevant proangiogenic
V, Almendro, P, Gascón
openaire   +2 more sources